TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10741706
Drug: 45 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 45 mg/m2 ATRA once daily
Study: 10741706
Drug: 90 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 mg/m2 ATRA once daily
Study: 10741706
Drug: 150 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg/m2 ATRA once daily
Study: 10741706
Drug: 15 mg/m2/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/m2/day ATRA every 8 h
Study: 10741706
Drug: ATRA pharmacokinetics
Normalized name: ATRA
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ATRA pharmacokinetics
Study: 8463519
Drug: 24% protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24% protein (61 g protein/L; n = 15)
Study: 8463519
Drug: 14% protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14% protein (37 g protein/L; n = 13)
Study: 3768576
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment (one or more of a selection of individually tailored, cognitive‐behavioural therapies lasting an average of 9.1 sessions)
Study: 3768576
Drug: Minimal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimal treatment (three or four sessions' assessment and advice)
Study: 30298859
Drug: 1.23% acidulated
Normalized name: Nupro APF 1.23% Acidulated Phosphate Fluoride Gel (Bubblegum)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.23% acidulated phosphate fluoride gel (APG)
Study: 30298859
Drug: 2% neutral
Normalized name: Perfect Choice 2% Neutral Topical Gel (Vanilla)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% neutral fluoride gel (NFG)
Study: 26297933
Drug: 0.9% sodium
Normalized name: LMD with 0.9% Sodium Chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% sodium chloride gel (control); n = 153
Study: 23661841
Drug: Combined supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined supplement of 40 mg zinc as zinc gluconate and 40 mg iron as ferrous sulphate
Study: 23661841
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg elemental iron as ferrous sulphate (Control)
Study: 17522789
Drug: Diclofenac low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac low-dose infusion
Study: 12665701
Drug: Risedronate 30
Normalized name: risedronate 30 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate 30 mg once weekly with vitamin D 400 iu daily and 1200 mg of calcium daily
Study: 12665701
Drug: Risedronate 30
Normalized name: risedronate 30 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate 30 mg once weekly
Study: 29028788
Drug: Pembrolizumab 2
Normalized name: pembrolizumab 25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 2 mg/kg every 3 weeks
Study: 25034862
Drug: Pembrolizumab 10
Normalized name: pembrolizumab 100 MG in 4 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 10 mg/kg every 3 weeks
Study: 22336221
Drug: Pemetrexed (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed (500 mg/m² every 21 days)
Study: 16845252
Drug: Candesartan 8
Normalized name: candesartan 8 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan 8 mg plus Ramipril 2.5 mg daily
Study: 14557145
Drug: High-frequency left-sided
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-frequency left-sided repetitive transcranial magnetic stimulation (HFL-TMS) applied daily for 4 weeks (20 5-second trains at 10 Hz)
Study: 14557145
Drug: Low-frequency right-sided
Normalized name: cured fat, pork side bacon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-frequency right-sided repetitive transcranial magnetic stimulation (LFR-TMS) applied daily for 4 weeks (five 60-second trains at 1 Hz)
Study: 8883115
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (500 mg calcium as calcium citrate malate per day)
Study: 8883115
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (500 mg calcium as calcium citrate malate per day) in subjects with above-median Tanner scores
Study: 3880688
Drug: Indomethacin sustained-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin sustained-release (ISR) oral preparation once a day at varying dosing times (8 a.m., noon, and 8 p.m.)
Study: 3880688
Drug: Indomethacin sustained-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin sustained-release (ISR) oral preparation at 8 a.m.
Study: 3880688
Drug: Indomethacin sustained-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin sustained-release (ISR) oral preparation at 8 p.m.
Study: 3880688
Drug: Indomethacin sustained-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin sustained-release (ISR) oral preparation with evening dosing
Study: 3880688
Drug: Indomethacin sustained-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin sustained-release (ISR) oral preparation with morning or noon dosing
Study: 3880688
Drug: Indomethacin sustained-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin sustained-release (ISR) oral preparation
Study: 31136263
Drug: Autologous PRP
Normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous PRP gel (3.5 ml ± 1.5 ml) injected at bone-tendon interface
Study: 31136263
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no PRP gel)
Study: 25186834
Drug: Loading-dose rosuvastatin
Normalized name: omadacycline 7-Day Oral Pack incuding loading dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loading-dose rosuvastatin 40 mg given 4 h before PCI
Study: 25186834
Drug: Conventional-dose rosuvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional-dose rosuvastatin 10 mg given 4 h before PCI
Study: 20660279
Drug: Blueberry supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blueberry supplementation (50 g freeze-dried blueberries, approximately 350 g fresh blueberries)
Study: 20660279
Drug: Control (960
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (960 mL water)
Study: 18778199
Drug: Peg‐Interferon alpha‐2a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peg‐Interferon alpha‐2a (180 microg weekly subcutaneously)
Study: 18778199
Drug: Peg‐Interferon alpha‐2b
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peg‐Interferon alpha‐2b (1.5 microg/kg weekly subcutaneously)
Study: 8896482
Drug: Iloprost regimen
Normalized name: Iloprost
DrugBank: Iloprost (DB01088)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iloprost regimen (intravenous at the beginning of the operation and three daily 6-hour infusions postoperatively, with an intragraft injection at completion of the bypass)
Study: 2053784
Drug: Nebulised acidic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulised acidic salbutamol solution
Study: 28677349
Drug: Anisodamine 10
Normalized name: Anisodamine
DrugBank: Anisodamine (DB11785)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anisodamine 10 mg
Study: 17287478
Drug: 45 mg
Normalized name: lutein 45 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 45 mg interleukin-12/23 monoclonal antibody
Study: 17287478
Drug: 90 mg
Normalized name: papain 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 mg interleukin-12/23 monoclonal antibody
Study: 17287478
Drug: four weekly
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: four weekly 45 mg interleukin-12/23 monoclonal antibody
Study: 17287478
Drug: four weekly
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: four weekly 90 mg interleukin-12/23 monoclonal antibody
Study: 17287478
Drug: interleukin-12/23 monoclonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: interleukin-12/23 monoclonal antibody
Study: 3301120
Drug: Intravenous streptokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous streptokinase (SK) 1‐h infusion of 1,500,000 IU
Study: 29314866
Drug: 900 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 mg/day spearmint extract
Study: 20110274
Drug: Iron treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron treatment with follow-up visits to provide IDA education
Study: 20110274
Drug: Iron treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron treatment with no follow-up
Study: 9692448
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of L-arginine administered during the first 30 minutes of cardioplegic arrest
Study: 9692448
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no L-arginine supplementation)
Study: 9692448
Drug: L-arginine group
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine group
Study: 9692448
Drug: L-arginine group
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine group and control group
Study: 20218011
Drug: Soft gelatin
Normalized name: Norvir Soft Gelatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soft gelatin capsule formulations of digoxin (0.4 mg) with in vitro burst times of 2.9 and 16 min
Study: 20218011
Drug: Soft gelatin
Normalized name: Norvir Soft Gelatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soft gelatin capsule formulations of digoxin (0.4 mg) with in vitro burst times of 62 and 229 min
Study: 20218011
Drug: All capsule
Normalized name: MemorAll Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: All capsule formulations
Study: 28956942
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ACT and WDI
Study: 25808074
Drug: Inhaled loxapine
Normalized name: loxapine Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled loxapine (15, 20, or 30 mg)
Study: 29468446
Drug: Long-term temozolomide
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term temozolomide therapy
Study: 29468446
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (short-term temozolomide)
Study: 16969592
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid 4 mg administered intravenously every 3 months
Study: 8818849
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg azithromycin, administered orally once daily for 3 days
Study: 8818849
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg roxithromycin, given orally twice daily for 10 days
Study: 30118904
Drug: Hybrid light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hybrid light activation (HL) with prior enamel acid etching (37% phosphoric acid for 15s) and 35% hydrogen peroxide gel (HP) applied for 3-4 consecutive applications with 2×3' activations (1' interval)
Study: 30118904
Drug: Hybrid light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hybrid light activation (HL) without prior enamel acid etching and 35% hydrogen peroxide gel (HP) applied for 3-4 consecutive applications with 2×3' activations (1' interval)
Study: 30118904
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (GIII and IV) without HL, receiving 35% hydrogen peroxide gel (HP) applied for 3×15' without HL
Study: 20846200
Drug: LEC group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: LEC group - levofloxacin 500 mg, esomeprazole 40 mg, clarithromycin 500 mg once daily for 7 days
Study: 20846200
Drug: AEC group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: AEC group - amoxicillin 1 g, esomeprazole 40 mg, clarithromycin 500 mg twice daily for 7 days
Study: 18223614
Drug: 26% dietary
Approvals — FDA: no, EMA: no, PMDA: no
Description: 26% dietary fat treatment
Study: 18223614
Drug: 34% dietary
Approvals — FDA: no, EMA: no, PMDA: no
Description: 34% dietary fat treatment
Study: 18223614
Drug: 40% dietary
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40% dietary fat treatment
Study: 16565237
Drug: Telmisartan (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan (40 to 80 mg)
Study: 10937427
Drug: Cough induced
Normalized name: Pediaclear Cough
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cough induced with inhaled citric acid
Study: 9017582
Drug: Cisplatin or
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin or carboplatin containing chemotherapy
Study: 1460118
Drug: Isotretinoin cream,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotretinoin cream, applied once nightly for 36 weeks
Study: 1460118
Drug: Vehicle cream,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle cream, applied once nightly for 36 weeks
Study: 6381871
Drug: Human insulin
Normalized name: Human insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Human insulin (0.075 IU/kg)
Study: 6381871
Drug: Porcine insulin
Normalized name: Porcine insulin
DrugBank: Insulin pork (DB00071)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Porcine insulin (0.075 IU/kg)
Study: 6381871
Drug: Human insulin
Normalized name: Human insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Human insulin (0.12 IU/kg)
Study: 6381871
Drug: Porcine insulin
Normalized name: Porcine insulin
DrugBank: Insulin pork (DB00071)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Porcine insulin (0.12 IU/kg)
Study: 6381871
Drug: Human insulin
Normalized name: Human insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Human insulin and Porcine insulin
Study: 26875824
Drug: R-CHOP/R-CVP (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-CHOP/R-CVP (standard therapy)
Study: 17577041
Drug: FU-based combination
Normalized name: fu ling
Approvals — FDA: no, EMA: no, PMDA: no
Description: FU-based combination chemotherapy
Study: 17577041
Drug: Gemcitabine combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine combination chemotherapy
Study: 7781622
Drug: Iatrogenic hypercortisolemia
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iatrogenic hypercortisolemia treatment for underlying diseases in pregnant women
Study: 31453961
Drug: Ospemifene 60
Normalized name: ospemifene 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ospemifene 60 mg daily
Study: 28658165
Drug: Endoscopic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic therapy (invasive procedures such as endoscopic injection sclerotherapy or endoscopic band ligation) for esophageal varices
Study: 16687711
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (88 mcg twice daily)
Study: 8219947
Drug: Senna-fibre combination
Normalized name: senna glycosides, combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Senna-fibre combination (10 ml daily)
Study: 8219947
Drug: Lactulose (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactulose (15 ml twice daily)
Study: 8219947
Drug: Senna-fibre combination
Normalized name: senna glycosides, combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Senna-fibre combination
Study: 3676920
Drug: L-Dopa (Sinemet)
Normalized name: α-methyl-L-dopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: L-Dopa (Sinemet)
Study: 29282600
Drug: Cytoreductive surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) with cisplatin 75 mg/m2 for 60 min at 43 °C
Study: 27092908
Drug: Intranasal wide
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal wide dissection
Study: 20520601
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg caffeine followed by 150 mg caffeine 90 min later
Study: 20520601
Drug: Caffeine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (100 mg and 150 mg)
Study: 12704369
Drug: Long synthetic
Normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long synthetic overlapping peptides (LSP) immunotherapy, 100 microg per peptide, injected at days 0, 4, 7, 14, 42, and 70.
Study: 1347267
Drug: Clemastine 2
Normalized name: clemastine 2 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clemastine 2 mg
Study: 31496423
Drug: Community empowerment-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community empowerment-based model of combination HIV prevention
Study: 27023447
Drug: TSH ≥
Normalized name: Thyroid Stimulating Hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: TSH ≥ 2.5 mIU/L
Study: 27023447
Drug: TSH <
Normalized name: Thyroid Stimulating Hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: TSH < 2.5 mIU/L
Study: 7724385
Drug: Epicardial patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epicardial patch (EPI)
Study: 23184900
Drug: 50,000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50,000 IU of oral ergocalciferol weekly for 12 weeks
Study: 19914548
Drug: Sequential treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential treatment arms
Study: 18184078
Drug: ddI +
Approvals — FDA: no, EMA: no, PMDA: no
Description: ddI + 1000 mg HU
Study: 18184078
Drug: ddI +
Approvals — FDA: no, EMA: no, PMDA: no
Description: ddI + 1500 mg HU
Study: 18184078
Drug: HU monotherapy
Normalized name: Hu-PHEC Liver
DrugBank: Hu-PHEC Liver (DB18347)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HU monotherapy
Study: 15700852
Drug: Gemcitabine (1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine (1,000 mg/m2 intravenously weekly for 7 weeks, followed by 1 week of rest, then weekly for 3 weeks every 4 weeks)
Study: 15700852
Drug: FLEC (5-fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: FLEC (5-fluorouracil 1,000 mg/m2, leucovorin 100 mg/m2, epirubicin 60 mg/m2, carboplatin 300 mg/m2 infused intra-arterially at a 3-week interval 3 times or 5-fluorouracil 400 mg/m2 plus folinic acid 20 mg/m2 for 5 days every 4 weeks for 6 cycles)
Study: 11240079
Drug: Behavior-oriented physical
Normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavior-oriented physical therapy (PT)
Study: 9855165
Drug: Weight loss
Normalized name: HERBAL WEIGHT LOSS AID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight loss and treatment with acetazolamide during a 24‐week period
Study: 8642232
Drug: Metoprolol (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (5 mg)
Study: 2728087
Drug: Bayesian dosing
Normalized name: Babesia microti preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bayesian dosing program for phenytoin
Study: 4157355
Drug: Aqueous procaine
Normalized name: Aqueous procaine penicillin G
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqueous procaine penicillin G (2,400,000 U for men; 2,400,000 U daily for 2 days for women)
Study: 4157355
Drug: Spectinomycin hydrochloride
Normalized name: Spectinomycin Hydrochloride
DrugBank: Spectinomycin (DB00919)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spectinomycin hydrochloride (2.0 g for men; 4.0 g for women)
Study: 25554757
Drug: Pilot intervention
Normalized name: Picot
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pilot intervention (immunization records obtained, immunization status determined, catch-up doses administered before discharge)
Study: 16505498
Drug: Benfluorex 450
Normalized name: benfluorex
DrugBank: Benfluorex (DB09022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benfluorex 450 mg/day
Study: 7990479
Drug: Oral Ftorafur
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Ftorafur (10 mg/kg daily)
Study: 7990479
Drug: Oral Ftorafur
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Ftorafur
Study: 31104111
Drug: Desensitizing gel
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desensitizing gel applied for 10 min before bleaching with 35% hydrogen peroxide, followed by placebo gel after.
Study: 31104111
Drug: Desensitizing gel
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desensitizing gel applied for 10 min before and after bleaching procedure.
Study: 31104111
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (desensitizing gel before and before & after)
Study: 22013799
Drug: Benzbromarone Tablet
Normalized name: benzbromarone
DrugBank: Benzbromarone (DB12319)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzbromarone Tablet (50 mg, once per day)
Study: 8557066
Drug: rhIGF‐I (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhIGF‐I (80 micrograms kg‐1 bw) subcutaneously twice daily
Study: 8557066
Drug: IGF‐I (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: IGF‐I (1 microgram mL‐1) in vitro
Study: 2172885
Drug: Megestrol acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megestrol acetate at a dose of 160 mg/day
Study: 2172885
Drug: Megestrol acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megestrol acetate at a dose of 480 mg/day
Study: 25072441
Drug: Nonoperative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonoperative treatment with antibiotics
Study: 28279659
Drug: Usual treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual treatment (1 session a day)
Study: 17240120
Drug: Escitalopram (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram (10 mg or 20 mg)
Study: 15524059
Drug: Atorvastatin 10-40
Normalized name: atorvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 10-40 mg daily
Study: 15524059
Drug: Atorvastatin 20
Normalized name: atorvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 20 and 40 mg daily
Study: 7930780
Drug: Intravenous secretin
Normalized name: Secretin
DrugBank: Secretin human (DB09532)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous secretin injection
Study: 30358724
Drug: Estrogen plus
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen plus progestogen therapy (EPT) - 0.625 mg conjugated equine estrogens plus 2.5 mg medroxyprogesterone acetate
Study: 19571077
Drug: 0.75% ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75% ropivacaine infusion at 5 mL/hr
Study: 19571077
Drug: 0.75% ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75% ropivacaine infusion